Ligand Pharmaceuticals (LGND) saw its stock price surge 5.91% in pre-market trading following the release of its impressive third-quarter financial results and an upward revision of its full-year guidance. The biopharmaceutical company significantly outperformed analysts' expectations, demonstrating robust growth across key financial metrics.

For the third quarter, Ligand reported adjusted earnings per share (EPS) of $3.09, handily beating the consensus estimate of $1.92. The company's revenue for the quarter reached $115.461 million, more than doubling from the previous year and surpassing the expected $58.795 million. This substantial revenue growth was primarily driven by higher royalty income and strategic transactions, including the sale of its Pelthos business.

In light of its strong performance, Ligand has raised its full-year 2025 guidance. The company now projects revenue between $225 million and $235 million, up from its previous forecast of $200 million to $225 million. Additionally, Ligand increased its adjusted EPS guidance to a range of $7.40 to $7.65, reflecting growing confidence in its operational efficiency and market position. The revised outlook has further fueled investor optimism, contributing to the significant pre-market stock price increase.